Weight-Loss Drugs: Boon or Bust?
Published on: Aug. 20, 2025, 10:26 a.m. | Source: Devdiscourse
Viking's weight-loss pill fails to meet expectations, causing a 41% share drop. Novo Nordisk's Wegovy gets U.S. approval for a liver condition, boosting shares. The European corporate profit outlook weakens, while U.S. allows emergency animal drug use for screwworms. EliseAI secures funding for healthcare expansion.
